Therapeutic
antibodies targeting programmed cell death 1 (PD-1) activate
tumor-specific immunity and have shown remarkable efficacy in the treatment of
melanoma. Yet, little is known about
tumor cell-intrinsic PD-1 pathway effects. Here, we show that murine and human
melanomas contain PD-1-expressing
cancer subpopulations and demonstrate that
melanoma cell-intrinsic PD-1 promotes
tumorigenesis, even in mice lacking adaptive immunity. PD-1 inhibition on
melanoma cells by RNAi,
blocking antibodies, or mutagenesis of melanoma-PD-1 signaling motifs suppresses
tumor growth in immunocompetent, immunocompromised, and PD-1-deficient
tumor graft recipient mice. Conversely,
melanoma-specific PD-1 overexpression enhances tumorigenicity, as does engagement of melanoma-PD-1 by its
ligand, PD-L1, whereas melanoma-PD-L1 inhibition or knockout of host-PD-L1 attenuate growth of PD-1-positive
melanomas. Mechanistically, the melanoma-PD-1 receptor modulates downstream effectors of mTOR signaling. Our results identify
melanoma cell-intrinsic functions of the PD-1:PD-L1 axis in
tumor growth and suggest that blocking melanoma-PD-1 might contribute to the striking clinical efficacy of anti-PD-1
therapy.